EU and US could reach trade deal this weekend - Reuters
On Tuesday, Unity Biotechnology Inc (NASDAQ: NASDAQ:UBX) saw its stock rating downgraded from Buy to Neutral by analysts at H.C. Wainwright, with a revised price target set at $2.00, down from the previous target of $4.00. The stock, currently trading at $0.78, has struggled recently, with InvestingPro data showing a steep 35.62% decline over the past six months. With a market capitalization of just $13.41 million, the company faces significant challenges ahead. This adjustment comes amid significant management shifts and the reevaluation of the company’s strategic direction, particularly in light of recent developments in its clinical programs.
The company has experienced a reshuffling of key executive roles, including the CEO, CFO, and Chief Legal Officer transitioning to consulting positions. This change in leadership occurs as Unity Biotechnology assesses various strategic alternatives for its future. Additionally, the company’s Phase 2B ASPIRE study, which compared its drug candidate UBX1325 with aflibercept in patients with diabetic macular edema (DME), failed to meet the primary endpoint of non-inferiority at weeks 20 and 24.
Despite this setback, UBX1325, which operates as a small molecule Bcl-xL inhibitor, has shown some promise in targeting the elimination of harmful senescent cells and inflammatory signaling in the retina. During the study, UBX1325 demonstrated non-inferiority to aflibercept at 9 of 10 time points through 36 weeks. Patients treated with UBX1325 experienced an improvement of 5.2 letters at week 24, with a slight increase to 5.5 letters at week 36, based on the initial analysis.
The failed primary endpoint was the mean change from baseline in best-corrected visual acuity (BCVA) averaged over weeks 20 and 24. The study continued to follow participants up to 36 weeks. While these results suggest some potential for the senolytic mechanism employed by UBX1325 in the treatment of retinal diseases, further clarity on the platform’s direction is needed before proceeding with development or seeking strategic partnerships. Investors awaiting the company’s next earnings report on July 22, 2025, can access deeper insights and additional analysis through InvestingPro, which offers exclusive financial metrics and real-time updates to help navigate this challenging biotech investment landscape.
In other recent news, Unity Biotechnology has released the complete 36-week results from its Phase 2b ASPIRE clinical trial for UBX1325, a treatment for diabetic macular edema (DME). The trial demonstrated that UBX1325 was statistically non-inferior to aflibercept, the current leading treatment, particularly in patients with less severe DME. Despite not meeting the primary endpoint at weeks 20 and 24, UBX1325 showed non-inferiority at nine out of ten time points through the 36-week period. Mizuho (NYSE:MFG) Securities recently downgraded Unity Biotechnology’s stock from ’Outperform’ to ’Neutral’ and slashed the price target from $6.00 to $1.00, citing technical trial challenges. Meanwhile, H.C. Wainwright maintained a Buy rating but adjusted its price target from $8.00 to $4.00, highlighting the drug’s potential in retinal disease treatment. Unity Biotechnology is also exploring strategic alternatives, including potential partnerships, to advance UBX1325’s development. The company aims to reduce operational costs and has approved a revised operating plan, including workforce reductions. Investors are closely watching for the full 36-week data, expected soon, which will inform further clinical development steps.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.